BR0311512A - Composição farmacêiutica com liberação retardada de substância ativa, processo para sua preparação - Google Patents

Composição farmacêiutica com liberação retardada de substância ativa, processo para sua preparação

Info

Publication number
BR0311512A
BR0311512A BR0311512-7A BR0311512A BR0311512A BR 0311512 A BR0311512 A BR 0311512A BR 0311512 A BR0311512 A BR 0311512A BR 0311512 A BR0311512 A BR 0311512A
Authority
BR
Brazil
Prior art keywords
pharmaceutical composition
mixture
preparation
active substance
delayed release
Prior art date
Application number
BR0311512-7A
Other languages
English (en)
Inventor
Hanshermann Franke
Peter Lennartz
Joern Raimer
Original Assignee
Desitin Arzneimittel Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=29432488&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR0311512(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Desitin Arzneimittel Gmbh filed Critical Desitin Arzneimittel Gmbh
Publication of BR0311512A publication Critical patent/BR0311512A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1635—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Abstract

"COMPOSIçãO FARMACêUTICA COM LIBERAçãO RETARDADA DE SUBSTâNCIA ATIVA, PROCESSO PARA SUA PREPARAçãO". A invenção refere-se a uma composição farmacêutica com liberação retardada de substância ativa, que é obtenível através de um processo de compactação especial, no qual não são necessários solventes orgânicos e água, e que se apresenta, de preferência, na forma de compartimentos individuais de substância ativa ou, por contato com meios aquosos, se decompõem naqueles compartimentos.
BR0311512-7A 2002-05-31 2003-05-15 Composição farmacêiutica com liberação retardada de substância ativa, processo para sua preparação BR0311512A (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE10224170A DE10224170A1 (de) 2002-05-31 2002-05-31 Pharmazeutische Zusammensetzung mit verzögerter Wirkstofffreisetzung
PCT/EP2003/005115 WO2003101428A1 (de) 2002-05-31 2003-05-15 Pharmazeutische zusammensetzung mit verzögerter wirkstofffreisetzung, verfahren zu derer zubereitung

Publications (1)

Publication Number Publication Date
BR0311512A true BR0311512A (pt) 2005-02-22

Family

ID=29432488

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0311512-7A BR0311512A (pt) 2002-05-31 2003-05-15 Composição farmacêiutica com liberação retardada de substância ativa, processo para sua preparação

Country Status (14)

Country Link
US (1) US20050202088A1 (pt)
EP (1) EP1509205B1 (pt)
JP (1) JP2005528428A (pt)
AT (1) ATE405252T1 (pt)
AU (1) AU2003236658A1 (pt)
BR (1) BR0311512A (pt)
CA (1) CA2485080A1 (pt)
DE (2) DE10224170A1 (pt)
DK (1) DK1509205T3 (pt)
ES (1) ES2312792T3 (pt)
MX (1) MXPA04011813A (pt)
NO (1) NO20045386L (pt)
PL (1) PL374041A1 (pt)
WO (1) WO2003101428A1 (pt)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL213565B1 (pl) * 2002-07-29 2013-03-29 Glaxo Group Ltd Preparat o przedluzonym uwalnianiu zawierajacy lamotrygine
EP1753398B1 (en) * 2004-06-10 2018-09-19 Glatt Air Techniques, Inc. Controlled release matrix pharmaceutical dosage formulation
EP1827385B1 (en) * 2004-11-23 2013-03-27 Adamas Pharmaceuticals, Inc. Pharmaceutical composition comprising memantine in an extended dosage release form for use in the treatment of dementias
CA2592605C (en) 2004-12-27 2010-12-07 Eisai R&D Management Co., Ltd. Method for stabilizing anti-dementia drug
AU2005325930B2 (en) * 2005-01-27 2012-01-19 Alembic Limited Extended release formulation of Levetiracetam
WO2006123357A2 (en) 2005-02-22 2006-11-23 Sun Pharmaceutical Industries Limited Oral controlled release composition containing levetiracetam
JP2008534522A (ja) * 2005-03-30 2008-08-28 ジェンファーム インク 医薬組成物のための複合ステップ製造方法
US20060252745A1 (en) 2005-05-06 2006-11-09 Almeida Jose L D Methods of preparing pharmaceutical compositions comprising eslicarbazepine acetate and methods of use
US7534381B2 (en) * 2005-09-14 2009-05-19 Isp Investments Inc. Process and apparatus for forming agglomerates of a powder composition of an active and binder
ATE429906T1 (de) * 2006-01-05 2009-05-15 Teva Pharma Trockene aripiprazolformulierungen
ES2318693T5 (es) * 2006-01-05 2018-10-04 Teva Pharmaceutical Industries Ltd Procedimiento de granulación en húmedo para la preparación de composiciones farmacéuticas de aripiprazol
EP2359830B1 (en) 2006-04-26 2012-09-19 Supernus Pharmaceuticals, Inc. Controlled released preparations of oxcarbazepine having sigmoidal release profile
AU2007248613A1 (en) * 2006-05-04 2007-11-15 Novartis Ag Heated roller compaction process for making pharmaceutical compositions
FI20060501L (fi) * 2006-05-22 2007-11-23 Biohit Oyj Koostumus ja menetelmä asetaldehydin sitomiseksi vatsassa
US20080014264A1 (en) * 2006-07-13 2008-01-17 Ucb, S.A. Novel pharmaceutical compositions comprising levetiracetam
WO2008062446A2 (en) * 2006-09-14 2008-05-29 Alembic Limited An extended release composition of levetiracetam, which exhibits no adverse food effect
GB0618879D0 (en) * 2006-09-26 2006-11-01 Zysis Ltd Pharmaceutical compositions
US7878430B2 (en) * 2006-11-20 2011-02-01 The University Of Western Ontario Method and apparatus for uniformly dispersing additive particles in fine powders
GB0700773D0 (en) 2007-01-15 2007-02-21 Portela & Ca Sa Drug therapies
US8372431B2 (en) 2007-10-26 2013-02-12 Bial-Portela & C.A., S.A. Pharmaceutical composition comprising licarbazepine acetate
US20110313037A1 (en) * 2008-12-20 2011-12-22 Saakian Susanna A [2.2.2] Bicyclic Derivatives and Methods of Use
CA2759807C (en) * 2009-04-23 2018-03-20 Sustained Nano Systems Llc Controlled release dispensing device
EP2298290A1 (en) 2009-09-16 2011-03-23 LEK Pharmaceuticals d.d. Controlled release composition comprising levetiracetam
CA2782556C (en) 2009-12-02 2018-03-27 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use
US9333175B2 (en) * 2010-06-16 2016-05-10 Mylan Inc. Controlled release levetiracetam formulations and methods for producing the same
WO2014204933A1 (en) 2013-06-17 2014-12-24 Adamas Pharmaceuticals, Inc. Amantadine compositions and methods of use

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB961813A (en) * 1963-03-18 1964-06-24 American Cyanamid Co Apparatus for densifying powdered materials
US4731122A (en) * 1987-03-30 1988-03-15 Alza Corporation Process for manufacturing a thermoplastic molding composition
TW487582B (en) * 1995-08-11 2002-05-21 Nissan Chemical Ind Ltd Method for converting sparingly water-soluble medical substance to amorphous state
ES2197064T3 (es) * 2000-10-24 2004-01-01 Fit Gmbh Granulado de agentes de desintegracion conjuntamente elaborados.

Also Published As

Publication number Publication date
DE10224170A1 (de) 2003-12-11
MXPA04011813A (es) 2005-07-26
DK1509205T3 (da) 2008-11-24
JP2005528428A (ja) 2005-09-22
PL374041A1 (en) 2005-09-19
EP1509205A1 (de) 2005-03-02
NO20045386L (no) 2004-12-09
ES2312792T3 (es) 2009-03-01
EP1509205B1 (de) 2008-08-20
ATE405252T1 (de) 2008-09-15
CA2485080A1 (en) 2003-12-11
WO2003101428A1 (de) 2003-12-11
DE50310366D1 (de) 2008-10-02
US20050202088A1 (en) 2005-09-15
AU2003236658A1 (en) 2003-12-19

Similar Documents

Publication Publication Date Title
BR0311512A (pt) Composição farmacêiutica com liberação retardada de substância ativa, processo para sua preparação
MX2008015621A (es) Agente medicinal para el tratamiento de obesidad, diabetes y enfermedades relacionadas con la tolerancia deteriorada de glucosa.
RS52607B (en) SOLID PHARMACEUTICAL COMPOSITIONS CONTAINING VALSARTAN
WO2004032905A8 (en) Gabapentin tablets and methods for their preparation
WO2004055006A8 (en) Novel compounds having selective inhibiting effect at gsk3
BRPI0417043A (pt) composição farmacêutica, forma de dosagem sólida, método de manufatura de forma de dosagem sólida, e, uso da composição
AU3475097A (en) Substituted cyclopentane compounds useful as neuraminidase inhibitors
TW200630123A (en) Oral medicinal product with modified release of at least one active principle in multimicrocapsular form
PT1104394E (pt) Mistura cimentosa de cura moldada
DK0575930T3 (da) Fremgangsmåde til fremstilling af faste farmaceutiske retardformer
ES2189768T3 (es) Sintesis regioselectiva de derivados de rapamicina.
DK1427297T3 (da) Appetitnedsættende procyanidin-holdigt præparat til pattedyr
WO2008100240A3 (en) Pharmaceutical composition with sodium lauryl sulfate as an extra-granular absorption/compression enhancer and the process to make the same
BR0009927B1 (pt) mÉtodo para produzir uma matriz de liberaÇço controlada, amàrfica ou parcialmente amàrfica insolével em Água.
ATE329581T1 (de) Pharmazeutische formulierung, die n-((1-n-butyl-4-piperidinyl)menthyl)-3,4-dihydr -2h-(1, 3)oxazino(3,2-a)indol-10-carboxamid oder ein entsprechendes salz hiervon enthält, sowie deren herstellungsprozess, welcher trockengranulierung beinhaltet
BR9913782A (pt) Processo de preparação de uma formualação galênica que compreende fenofibrato como princìpio ativo, formulação galênica, medicamento e utilizações de um meio lìquido e de partìculas de fenofibrato
BR0107899A (pt) Processo para produzir uma preparação de ingrediente ativo compreendendo ibuprofeno, preparação de ingrediente ativo, uso da mesma, preparação farmacêutica, uso da mesma, processo para produzir formas de dosagem sólidas, e, forma de dosagem sólida
UA98621C2 (ru) Гомеопатическое лекарственное средство для лечения ожирения, сахарного диабета и заболеваний с нарушением толерантности к глюкозе
BRPI0518847A2 (pt) processo para a preparaÇço de uma forma farmacÊutica sàlida oralmente dispersÁvel, e, forma farmacÊutica sàlida oralmente dispersÁvel
NO20055016L (no) Farmasoytisk sammensetning som fast doseringsform og fremgangsmate for fremstilling derav
WO2007026261A3 (en) Formulations containing losartan and/or its salts
EP1123692A3 (fr) Utilisation de dérivés de polyaminoacides pour traiter la séborrhée et les désordres cutanés associés
BR9908838A (pt) Uso de um glicocorticóide, processeo para tratar glomerulonefrite aguda ou crÈnica, e, composição farmacêutica para tratar glomerulonefrite
DE69103724D1 (de) Pharmazeutische zusammensetzungen mit verzögerter freisetzung zur oralen verabreichung sowie deren herstellungsverfahren.
HUP0500512A2 (hu) Megnövelt dózisú nelfinavir tabletta és eljárás a tabletta előállítására

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 6A E 7A ANUIDADES

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO PUBLICADO NA RPI 2064 DE 27/07/2010.